Atrys Health : Q3 2023 trading update a touch above expectations, guidance reiterated
>Organic sales momentum remains strong - Q3 2023 group sales were € 51m (+11% y-o-y vs +33% in H1 2023 and +55% in FY 2022) the normalisation of sales growth was due to the end of the scope effect on Bienzobas (acquired in July 2022), while the group continues to benefit from the scope effect on Chilerad and Initia (acquired in December 2022) which contributed with 2-3pp of the group’s sales growth over the quarter, on our estimates, implying organic growth of +8-9%, ...Atrys Health SA. Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.